USFDA approves Zydus copy of cholesterol drug Colestid
The Hindu
“The Abbreviated New Drug Application of the company is only the second generic application approved by USFDA for this product,” Zydus said
Zydus Lifesciences has received final approval from the U. S. Food and Drug Administration (USFDA) to market its generic version of cholesterol lowering drug Colestipol Hydrochloride tablets, in the strength of 1mg.
“The Abbreviated New Drug Application (ANDA) of the company is only the second generic application approved by USFDA for this product,” Zydus said. “The approved product, which is a generic version of Colestid, will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad,” it said.
“Colestipol Hydrochloride is a highly complex macro molecule drug substance with little or no systemic absorption. The tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet,” Zydus Lifesciences (formerly known as Cadila Healthcare) said.
“The group now has 330 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04,” it said.
AAP's Raghav Chadha calls for banning 10-minute delivery services, highlighting the harsh conditions faced by gig workers.
IndiGo flight cancellations: Follow LIVE updates from The Hindu as IndiGo's operations face issues with over 400 flights cancelled today.
DGCA grants IndiGo exemption from night-duty limits for pilots amid widespread flight cancellations and operational disruptions.
RBI to launch a two-month campaign in January 2026 to address pending grievances with the Ombudsman for improved customer service.
RBI plans ₹1 lakh crore OMO in December to boost liquidity amid upcoming tax payments, ensuring stability in the banking system.
IndiGo faces ongoing flight delays and cancellations due to technology issues, weather, and new crew rostering rules.
Stock markets experience volatility as investors await RBI's monetary policy amid foreign fund outflows and mixed global trends.
ED attaches assets worth ₹1,120 crore in Anil Ambani's Reliance Group case, totaling ₹10,000 crore amid money laundering probe.
Rupee rises 20 paise to 89.69 against the dollar as investors await RBI's monetary policy decision amidst market pressures.
Just nine Fugitive Economic Offenders (FEOs) owed Indian banks over ₹58,000 crore in principal and interest. To date, banks have recovered just over ₹19,000 crore — roughly 33% of the total dues.
Commerce Minister Piyush Goyal urges Indian businesses to seize opportunities in Russia's market, addressing talent shortages and trade demands.
Premiumisation is driving the growth in beauty and personal care industry in India and this segment is growing faster than the products made for the masses, industry executives said at Cosmoprof India 2025, a beauty & personal care industry event currently underway in Mumbai.
Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.